An Extensive Therapeutical Drug Monitoring Repository for Localized Population Pharmacokinetics Research

Year 2024, Volume: 11 Issue: 3, 93 - 108, 31.12.2024

Elif Çakır Pınar Öz , Murat Ozdemir Selma Ozilhan Nevzat Tarhan

https://doi.org/10.32739/jnbs.11.1608197

Abstract

Aim: The study's long-term goals, such as determining supratherapeutic ranges according to age distributions specific to the country, adjusting dosages for additional drugs used by patients in different disease groups, and providing the opportunity for etiological studies in the light of diagnosis and drug metabolism perspective, are of great importance in defining the study. Method: Population pharmacokinetics is a method expressed to evaluate processes such as absorption, distribution, metabolism, and elimination of a drug from an individual's blood-plasma concentration. In drug pharmacokinetic experiments, generating data without considering any pharmacokinetic differences among patients prevents the measurement or observation of variability among individuals in the population as a simple approach. The dose-concentration relationship is crucial for individualized dose adjustment. Additionally, the impact of other drugs used by the individual on metabolite levels and the metabolic interactions between drugs play a critical role in the development of personalized treatments. Population approaches provide a foundation that benefits the observation of these effects. The variability in drug metabolism among individuals forms one of the fundamental building blocks of personalized treatment approaches, specifically through Therapeutic Drug Monitoring (TDM), which plays an important role in determining the therapeutic range of drugs. Materials: In this study, drug metabolism findings of patients served at NP Istanbul Brain Hospital between 2010 and 2022 were examined within the repository created along with other patient-specific parameters. Results and Conclusion: The analysis results have been followed up longitudinally, partially demographically, and retrospectively. Thanks to the repository of NP Istanbul Brain Hospital, population pharmacokinetic analyses aimed in this study are being conducted for the first time globally and nationally in terms of scope. The repository has been studied with TDM for individualized treatment methods, and within this project, it is anticipated to perform phenotyping with the population pharmacokinetic approach.

Keywords

Pharmacokinetics, Population Pharmacokinetics, Psychiatric Drugs, Statistical Analysis, Therapeutic Drug Monitoring

References

• 1. Aimone, L. D., & de Lannoy, I. A. M. (2014). Overview of Pharmacokinetics. Current Protocols in Pharmacology, 7.1.1–7.1.31. doi:10.1002/0471141755.ph0701s66
• 2. Ansermot, N., Brawand-Amey, M., Kottelat, A., & Eap, C. B. (2013). Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. Journal of Chromatography a, 1292, 160-172, DOI: 10.1016/j.chroma.2012.12.071
• 3. Batchelor, H. K., & Marriott, J. F. (2015). Paediatric pharmacokinetics: key considerations. British Journal of Clinical Pharmacology, 79(3), 395–404. doi:10.1111/bcp.12267
• 4. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004;38(10):1702-1706, 391, DOI: 10.1345/aph.1D374
• 5. Fan, J., & de Lannoy, I. A. M. (2014). Pharmacokinetics. Biochemical Pharmacology, 87(1), 93–120. doi:10.1016/j.bcp.2013.09.007
• 6. Fekete, S., Scherf-Clavel, M., Unterecker, S., Egberts, K., Gerlach, M., Romanos, M., & Kittel-Schneider, S. (2020). Dose-Corrected Serum Concentrations and Metabolite to Parent Compound Ratios of Venlafaxine and Risperidone from Childhood to Old Age. Pharmacopsychiatry, 54(03), 117–125. doi:10.1055/a-1302-8108
• 7. Goutelle, S., Woillard, J., Neely, M., Yamada, W., & Bourguignon, L. (2020). Nonparametric Methods in Population Pharmacokinetics. The Journal of Clinical Pharmacology. doi:10.1002/jcph.1650
• 8. Goutelle, S., Woillard, J., Buclin, T., Bourguignon, L., Yamada, W., Csajka, C., Neely, M. and Guidi, M. (2022). Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts’ Discussion on Use, Strengths, and Limitations. The Journal of Clinical Pharmacology 2022, 62(2) 158–170. DOI: 10.1002/jcph.1993
• 9. Guidi, M., Csajka, C., & Buclin, T. (2020). Parametric Approaches in Population Pharmacokinetics. The Journal of Clinical Pharmacology. doi:10.1002/jcph.1633
• 10. Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., . . . Greiner, C. (2018). Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry, 51(01/02), 9-62, DOI: 10.1055/s-0043-116492
• 11. Kim, K.-B., Seo, K.-A., Kim, S.-E., Bae, S. K., Kim, D.-H., & Shin, J.-G. (2011). Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography/tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis, 56(4), 771-777, PMID: 21840666, DOI: 10.1016/j.jpba.2011.07.019
• 12. Mould DR, Upton RN. Basic concepts in population mod- eling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38, DOI: 10.1038/psp.2013.14 13. Sempio, C., Morini, L., Vignali, C., & Groppi, A. (2014). Simple and sensitive screening and quantitative determination of 88 psychoactive drugs and their metabolites in blood through LC–MS/MS: Application on postmortem samples. Journal of Chromatography B, 970, 1-7, DOI: 10.1016/j.jchromb.2014.08.039
• 14. Sheehan, J., Sliwa, J., Amatniek, J., Grinspan, A., & Canuso, C. (2010). Atypical antipsychotic metabolism and excretion. Current drug metabolism, 11(6), 516-525, DOI: 10.2174/138920010791636202
• 15. Sun, H., Fadiran, E. O., Jones, C. D., Lesko, L., Huang, S., Higgins, K., … Ette, E. I. (1999). Population Pharmacokinetics. Clinical Pharmacokinetics, 37(1), 41–58. doi:10.2165/00003088-199937010-00003
• 16. Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH. Funda- mentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51(9):573-590, DOI:10.2165/11634200-000000000-00000
• 17. Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet. 1996;30(2):81-93, doi: 10.2165/00003088-199630020-00001